成人Diamond-Blackfan贫血综合征的血液学特征
基于法国DBAS注册库分析235例成人患者,发现除贫血外中性粒细胞减少和血小板减少常见且持续,即使无需治疗者仍有52%贫血;MDS和AML发生风险显著超额且预后差;中位随访32.2年,30、40、50年总生存率分别为98.0%、90.6%、70.7%。
要点
- 成人DBAS中贫血、中性粒细胞减少、血小板减少和全血细胞减少分别占78%、31%、15%和11%。
- 无需DBAS特异性治疗者贫血、中性粒细胞减少和血小板减少发生率仍达52%、35%和10%。
- MDS和AML观察值与预期值比分别为155和55.4,且均伴高危特征和不良结局。
核心结论
- 成人DBAS中贫血以外的血细胞减少常见且持续,髓系肿瘤发生率高且结局差,需风险分层和优化治疗策略。
研究设计与样本
- 基于法国DBAS注册库的回顾性分析,纳入235例成人DBAS患者,中位随访32.2年(IQR 26-44)。
主要发现
- 末次随访时贫血、中性粒细胞减少、血小板减少和全血细胞减少分别影响78%、31%、15%和11%的患者。
- 无克隆演化者未发生严重再生障碍性贫血。
- 无需DBAS特异性治疗(如类固醇或红细胞输注)者贫血、中性粒细胞减少和血小板减少发生率分别为52%、35%和10%。
- 4例发生MDS或AML,均伴高危特征且结局不良;MDS和AML的观察值与预期值比分别为155和55.4。
- 30、40、50年总生存率分别为98.0%(95%CI 95.8-100)、90.6%(95%CI 84.2-97.5)和70.7%(95%CI 57.3-87.2);实体瘤和血液系统肿瘤是主要死因。
关键数值与推荐
- 贫血、中性粒细胞减少、血小板减少和全血细胞减少分别占78%、31%、15%和11%。
- 无需DBAS特异性治疗者贫血、中性粒细胞减少和血小板减少发生率分别为52%、35%和10%。
- MDS和AML的观察值与预期值比分别为155和55.4。
- 30、40、50年总生存率分别为98.0%(95%CI 95.8-100)、90.6%(95%CI 84.2-97.5)和70.7%(95%CI 57.3-87.2)。
临床怎么用
- 对成人DBAS应超越贫血评估,系统监测中性粒细胞和血小板减少。
- 治疗独立不等于血液学缓解,需持续血液学随访。
- 对MDS/AML保持高度警惕,发现异常应及时评估并考虑风险分层监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Information about Diamond-Blackfan anemia syndrome (DBAS), a ribosomopathy associated with anemia, congenital anomalies and cancer predisposition is limited in adults. Using the French DBAS registry, 235 adult patients with DBAS were analyzed for hematological outcomes. At last follow-up, anemia, neutropenia, thrombocytopenia, and pancytopenia affected respectively 78%, 31%, 15%, and 11% of the patients. There was no severe aplastic anemia outside of clonal evolution. Among patients without DBAS-specific treatment (e.g., steroids or red blood cell transfusions), the incidence of anemia, neutropenia, and thrombocytopenia was 52%, 35%, and 10%, highlighting that treatment independence does not mean hematologic remission. Four patients developed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), all associated with poor-risk features and dismal outcomes. Observed to expected ratios were 155 for MDS and 55.4 for AML, confirming a major risk-excess despite stringent criteria for MDS diagnosis. With a median follow-up of 32.2 years (IQR 26-44), overall survival (OS) was 98.0% (95% CI, 95.8-100), 90.6% (95% CI, 84.2-97.5), and 70.7% (95% CI, 57.3-87.2) at 30, 40, and 50 years respectively. Solid and hematologic cancers were the main cause of death. This study demonstrates, in a large cohort of adults with DBAS, that cytopenias beyond anemia are frequent and persistent. Myeloid neoplasms occur with a high incidence and dismal outcomes. These findings highlight the need for risk stratification, tailored surveillance, and optimized therapeutic strategies in this vulnerable population.
引用
- Lecornec N, de Fontbrune FS, Forcade E, et al. Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome. Am J Hematol. 2026. PMID: 41498485. doi:10.1002/ajh.70197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。